The latest directive has come in a case where the association was found to have violated competition norms with respect to the practice of issuance of no objection certificate for appointment of stockists.
The complaint by Belgaum District Chemists and Druggists Association (BCDA) was filed against KCDA as well as Abbott India, Geno Pharmaceuticals and All India Organisation of Chemists And Druggists (AIOCD).
It was alleged that Abbott India and Geno Pharmaceuticals refused to supply drugs to the members of BCDA as they did not have No Objection Certificates from KCDA or AIOCD.
The determination of trade margins for wholesalers and retailers by KCDA "is in contravention" of the provisions of Section 3 of the Competition Act, the regulator noted.
Section 3 pertains to anti-competitive agreements.
The watchdog has asked the association to cease and desist from unfair business practices.
"Commission directs OP 2 (KCDA) to cease and desist from indulging in the practice of mandating No Objection Certificate as a pre-requisite for appointment of stockist and fixing of trade margins for retailers and wholesalers, which have been held to be anti-competitive...," it said in an order issued on Thursday.
"Recently a penalty of Rs 8,60,321 was imposed upon OP 2 in a matter involving similar allegations i.E. NOC practice for appointment of stockist. The period of contravention in the said case was subsequent to the period of investigation in the instant matter.
"In view of these, the Commission refrains from imposing any monetary penalty in the present case," the order said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
